Activin signaling inhibitors
Activin signaling inhibitors are medicines that block signals carried by activin and related growth factors. The US label of Winrevair (sotatercept) calls it an activin signaling inhibitor that binds activin A and other growth factors of the same family, and says this improves the balance between signals that drive and signals that hold back the growth of blood vessel cells. A narrative review published in November 2026 calls targeting BMP/activin signaling a major advance in pulmonary arterial hypertension, and says a treatment framework recognizes it as a fourth treatment pathway alongside endothelin, nitric oxide and prostacyclin. Sotatercept is the only medicine in this group so far, and it has its own page. This is the class page.
Also called Activin Signaling Inhibitor · Activin Signaling Inhibitors
- Drug
- In this atlas
Overview
Technical summary
Class page. The name and aliases use the RxClass class names: the established pharmacologic class on US drug labels Activin Signaling Inhibitor (EPC, class N0000194100) and the mechanism-of-action class Activin Signaling Inhibitors (read 2026-11-19). RxClass lists sotatercept as the only member of the EPC class, so sotatercept is filed here on that evidence. MeSH has descriptors for activins and activin receptors, which are the target and not the medicine class, so no MeSH identifier is recorded. Sources: the Winrevair label (BLA761363, effective 2026-09-21), whose mechanism section describes the class action, and a 2026 narrative review (PMC13764490, Journal of Clinical Medicine, CC BY 4.0) that describes BMP/activin signaling as a treatment pathway in pulmonary arterial hypertension. The review attributes the four-pathway framework to the 7th World Symposium on Pulmonary Hypertension; that document was not read. No trial result, dose or instruction is recorded.
Drugs in this class
1 drug in this atlas is filed under Activin signaling inhibitors, with the registry trials and FDA regulatory decisions this atlas holds for each. With Activin signaling inhibitors itself, the class has 0 distinct trials and 0 distinct FDA decisions; a trial or decision that two of them share counts once there.
About this drug
- Level
- Class
- Mechanism
- The Winrevair label says sotatercept-csrk is an activin signaling inhibitor that binds to activin A and other TGF-beta superfamily ligands, and improves the balance between pro-proliferative and anti-proliferative signaling to modulate vascular proliferation.
Claims and evidence
No claims are published for this drug yet.
Record details
- Record id
cardio:activin-signaling-inhibitors- Content hash
a7cdcf47ac45192a1f23f1754b425e2bb8ccd478f304a0927a1ab30ee09828a8